Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 10/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18382156 | 0.85 | MAPKAPK2 (0.58) | MAPKAPK2PIK3CGPIK3CAPIK3CDPIK3CB | |
| SCHEMBL18382162 | 0.85 | MAPKAPK2 (0.73) | MAPKAPK2PIK3CGPIK3CAPIK3CDPIK3CB | |
| SCHEMBL18382154 | 0.85 | MAPKAPK2 (0.73) | MAPKAPK2PIK3CGPIK3CAPIK3CDPIK3CB | |
| SCHEMBL17047432 | 0.84 | PIK3CG (0.74) | PIK3CGPIK3CAPIK3CDPIK3CB | |
| SCHEMBL18382169 | 0.82 | MAPKAPK2 (0.59) | MAPKAPK2PIK3CGPIK3CAPIK3CDPIK3CB | |
| SCHEMBL18382172 | 0.82 | MAPKAPK2 (0.62) | MAPKAPK2PIK3CGPIK3CAPIK3CDPIK3CB | |
| SCHEMBL18382155 | 0.81 | PIK3CG (0.71) | MAPKAPK2PIK3CGPIK3CAPIK3CDPIK3CB | |
| SCHEMBL18382146 | 0.80 | MAPKAPK2 (0.49) | MAPKAPK2PIK3CGPIK3CAPIK3CDPIK3CB | |
| SCHEMBL18382202 | 0.80 | MAPKAPK2 (0.73) | MAPKAPK2PIK3CGPIK3CAPIK3CDPIK3CB | |
| SCHEMBL18382157 | 0.79 | PIK3CG (0.71) | MAPKAPK2PIK3CGPIK3CAPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170015662-A1 | 6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015662-A1 | 6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS | PIK3CA, PI4KA, PDPK1 | MAPKAPK2 55/4885PIK3CG 5/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.